SUMMARY
Genes whose function is selectively essential in the presence of cancer-associated genetic aberrations represent promising targets for the development of precision therapeutics. Here, we present CancerGD, a resource that integrates genotypic profiling with large-scale loss-of-function genetic screens in tumor cell lines to identify such genetic dependencies. CancerGD provides tools for searching, visualizing, and interpreting these genetic dependencies through the integration of functional interaction networks. CancerGD includes different screen types (siRNA, shRNA, CRISPR), and we describe a simple format for submitting new datasets.
The ability to inhibit tumors in molecularly defined cohorts of patients is a cornerstone of precision cancer treatment. A successful approach has been the development of drugs that inhibit proteins specifically required in tumors harboring aberrations in recurrently altered cancer driver genes (Luo et al., 2009) . For example, oncogene addiction effects, such as the increased sensitivity of ERBB2 (HER2)-amplified breast tumors to ERBB2 inhibitors (Hynes and Lane, 2005) , can be clinically exploited, as can non-oncogene addiction effects, such as the synthetic lethal relationship between BRCA1/BRCA2 mutations and PARP inhibitors (Lord et al., 2015) . To identify additional cancer genetic dependencies (CGDs) that may ultimately be exploited therapeutically, multiple groups have performed large-scale loss-offunction genetic screens in panels of tumor cell lines Campbell et al., 2016; Cheung et al., 2011; Cowley et al., 2014; Marcotte et al., 2012 Marcotte et al., , 2016 Wang et al., 2017) . Integrating the results of these screens with molecular profiling data creates hypothesis-generating resources where the hypotheses are of the form ''tumor cells with a mutation in gene X are sensitive to inhibition of gene Y.'' These hypotheses are typically tested in subsequent experiments-for example, in larger panels of cell lines, using orthogonal mechanisms of gene inhibition, and/or in mouse models-to ensure they are not statistical or experimental artifacts. Recent examples of novel CGDs discovered through genetic screening approaches include an increased sensitivity of ARID1A mutant cell lines to inhibition of the ARID1A paralog ARID1B (Helming et al., 2014) , of PTEN mutant breast tumor cell lines to inhibition of the mitotic checkpoint kinase TTK , and of MYC-amplified breast tumor cell lines to inhibition of multiple distinct splicing components (Hsu et al., 2015) .
Although the results of loss-of-function screens are typically made publically available, their integration with genotypic data remains challenging for those without bioinformatics skills. Sequencing and copy-number data must be processed to identify likely functional alterations, cell line names matched between different data sources, and statistical analysis performed to identify associations between the alteration of driver genes and an increased sensitivity to inhibition of target genes. To address these challenges, we have developed CancerGD (www. cancergd.org), a resource that integrates multiple loss-of-function screens Cowley et al., 2014; Marcotte et al., 2012 Marcotte et al., , 2016 Wang et al., 2017) with genotype data (Forbes et al., 2015; Iorio et al., 2016; Yang et al., 2013) to identify CGDs associated with a panel of cancer driver genes (Figure 1) .
CancerGD currently facilitates the searching, visualization, and interpretation of CGDs ( Figure 1 ) associated with 53 driver genes (Table S1 ). These genes were selected based on their identification as driver genes in multiple independent analyses Forbes et al., 2015; Vogelstein et al., 2013) and due to their alteration in at least three tumor cell lines featured in one or more of the included loss-of-function screens. Driver-gene-associated CGDs are identified both across cell lines from multiple histologies (Pan cancer) and within tumor cell lines arising from specific primary sites (e.g., Breast). With an intuitive search interface, it is thus possible to retrieve CGDs associated with ERBB2 amplification across cell lines from all tissue types or specifically associated with ERBB2 amplification in breast tumor models (Figure 2A ). The data supporting every CGD can be visualized in an interactive boxplot ( Figure 2B ) and downloaded for reference.
Aside from oncogene addiction effects (Luo et al., 2009 ), which represent a tiny minority of the dependencies stored in CancerGD, the mechanistic interpretation of CGDs remains challenging. Why would mutation of one gene result in an increased dependency upon another? In yeast, the interpretation of such relationships has been greatly aided by the integration of protein-protein interaction networks with genetic screens (Kelley and Ideker, 2005) . Following a similar model, to aid the interpretation of CGDs in CancerGD, we integrate functional interactions from the STRING database (Szklarczyk et al., 2015) . This facilitates the rapid identification of CGDs involving gene pairs with known functional relationships. For instance, in the Campbell et al. (2016) dataset ERBB2 amplification is associated with an increased dependency upon the ERBB2 protein interaction partners JAK2 and ERBB3, as well as the ERBB2 downstream effector PIK3CA (Figure 2A ). Similarly in the Cowley et al. (2014) dataset loss or mutation of the BAF complex subunit ARID1A is associated with an increased dependency upon the ARID1A paralog and BAF complex member ARID1B (Helming et al., 2014) . Such dependencies may make more promising candidates for follow-on experiments as they are supported by existing functional relationships in addition to the genetic association.
In addition to identifying known functional interactions between the driver gene and associated dependency, it can be helpful to understand the relationships between all of the CGDs associated with a given driver gene. For instance, we previously found that cell lines with a deletion or mutation of the tumor suppressor SMAD4 display a strong dependency upon Loss-of-function screens from multiple sources are integrated with exome and copy-number profiles from the GDSC resource. Cell lines are annotated according to the mutational status of a panel of driver genes (see Table S1 ). Statistical analysis is then performed to identify associations between the presence of driver gene alterations and sensitivity to reagents targeting specific genes. These CGDs are filtered such that only those with nominal significance (p < 0.05) and moderate common language effect sizes (R65%) are retained. Finally, all CGDs are annotated according to whether they occur between drivertarget pairs with known functional relationships (STRING) and whether there is an inhibitor available for the target gene (DGIdb).
the mitotic checkpoint kinase CHEK1 . Considered in isolation, it is not clear whether this CGD relates to a specific function of CHEK1 or a more general sensitivity to inhibition of the mitotic checkpoint. However, by analyzing all of the dependencies associated with SMAD4, we found that they were densely connected on the protein interaction network and primarily involved in the mitotic checkpoint , suggesting a more general sensitivity to perturbation of this pathway. To facilitate the identification of such pathway-level dependencies, CancerGD provides network visualizations of the functional interactions between CGDs associated with each driver gene ( Figure S1 ).
In contrast to the results of drugscreening efforts in panels of tumor cell lines (Barretina et al., 2012; Basu et al., 2013; Daemen et al., 2013; Garnett et al., 2012; Iorio et al., 2016; Yang et al., 2013) , the CGDs identified in lossof-function screens include targets that have no inhibitors available and consequently may serve as the rationale for the development of new small-molecule inhibitors. To facilitate the identification of CGDs that may be more readily exploited with available inhibitors, CancerGD integrates drug-gene interaction relationships from DGIdb (Griffith et al., 2013) .
It has previously been highlighted that many CGDs identified in one loss-of-function screen are not evident in additional datasets (Brough et al., 2011a; Downward, 2015) . This could indicate that these CGDs are context specific (Ashworth et al., 2011) but can also be explained by a variety of technical factors. Different screens feature different coverage of gene libraries (e.g., kinome versus genome-wide), different coverage of cancer types (e.g., only melanoma in one versus only breast in another), and different coverage of driver genes (e.g., many BRAF mutant cell lines in one screen versus none in another). These technical factors can result in the identification of CGDs in one screen that cannot be observed in a second screen. Furthermore, in any given screen there may be false positives resulting from the off-target effects of gene-targeting reagents (Jackson and Linsley, 2010) and false negatives resulting from variation in the knockdown efficiencies of different gene-targeting reagents (Kaelin, 2012) . There are thus a number of explanations for why a CGD observed in one dataset may not be evident in another. Nonetheless, the CGDs that are observed in multiple datasets may be of particular interest as they are perhaps less likely to result from the off-target effects of gene-targeting reagents Columns display experimental details along with the p value, common language effect size, and difference in median sensitivity score for each dependency. Genes identified as dependencies in multiple datasets are indicated in the Multiple Hit column. Genes with a known functional relationship to the driver gene (e.g., PIK3CA) are indicated in the String Interaction column, and drugs known to inhibit the target gene are indicated in the Inhibitors column. Toggles/search boxes permit easy filtering of interactions, e.g., to select only those genes with an associated inhibitor available. See also Figure S1 and the tutorial in Methods S1. (B) Example boxplot showing an increased sensitivity of ERBB2-amplified cell lines to inhibition of MAP2K3. Each data point represents the sensitivity of a particular cell line to RNAi reagents targeting MAP2K3. Cell lines are grouped according to ERBB2 amplification status with the wild-type group on the left and amplified group on the right. Cell lines are colored according to site of origin and toggles on the right permit the hiding/showing of cell lines from specific sites. Hovering over a given data point provides the cell line's name, the primary site, and the score associated with the RNAi reagent in that cell line. An overlapped box-whisker plot displays the interquartile range and the median for each group. High-resolution PNG images for each boxplot can be downloaded along with a CSV file containing all of the data presented in the boxplot. Links to the target gene (MAP2K3) on external websites are provided at the bottom of the plot. and also less likely to be highly context specific. In CancerGD, we provide functionality to identify and filter those CGDs observed independently in multiple datasets.
CancerGD can incorporate datasets generated using different experimental and computational pipelines and is not restricted to loss-of-function screens generated using any specific method (shRNA/siRNA/CRISPR). The main requirement for inclusion is that a dataset must contain the results of screens in a panel of cell lines (a minimum of ten cell lines) and provide some quantitative measurement of the sensitivity of each cell line to the inhibition of each gene screened. Currently, the resource includes three genome-scale shRNA screens Marcotte et al., 2012 Marcotte et al., , 2016 , one kinome-wide siRNA screen , and one genome-wide CRISPR screen . As additional screens become available, we will incorporate their results into the resource (see STAR Methods for instructions on how to format screens for easy inclusion in CancerGD).
A tutorial demonstrating the full functionality of CancerGD is provided in Supplemental Information. We believe that CancerGD will be a useful resource to aid a wider group of cancer researchers to benefit from the information generated in large-scale loss-of-function screens.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: 
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Loss of Function Screens
Four large-scale RNAi datasets and one CRISPR dataset are currently included in CancerGD Cowley et al., 2014; Marcotte et al., 2012 Marcotte et al., , 2016 Wang et al., 2017) . These include a kinome focussed siRNA screen covering a panel of 117 cell lines from diverse histologies , a genome-scale shRNA screen focussed on 77 breast tumor cell lines , a genome-scale shRNA screen focussed on 72 breast, ovarian and pancreatic cell lines , a large-scale shRNA screen covering 216 cell lines from diverse histologies , and a genome-scale CRISPR screen covering 14 AML cell lines . Cowley et al is largely a superset of a previous screen from the same lab (Cheung et al., 2011) and hence the two resources are not included separately. Similarly the kinome siRNA screen from Cambell et al contains the majority of the breast tumor cell lines screened in a previous breast cancer kinome siRNA screen from the same lab ) and hence they are not included separately. The breast cell lines in are a superset of those included in ) and consequently we do not store breast specific dependencies from .
Cell Line Naming
Internally we follow the naming convention established by the Cancer Cell Line Encyclopedia (Barretina et al., 2012) . The CCLE naming convention is the cell line name (containing only numbers and upper case letters) followed by an underscore, followed by the tissue/primary site in upper case. The cell line names are taken from (Iorio et al., 2016) , converted to uppercase and punctuation removed. Where possible we use the same tissue types as the CCLE, in a small number of cases where a tissue was absent from the CCLE (e.g. CERVIX) we have created a new tissue type. Having the tissue type in the cell line name facilitates filtering the boxplots (e.g. to show the gene inhibition sensitivities for cell lines from a specific tissue) in the browser without having to perform additional database queries. Furthermore two of the published loss-of-function screens already follow this naming convention Cowley et al., 2014) while a third features only breast cell lines and was trivially converted . In instances where the same cell line is featured in two datasets but there is a naming disagreement (e.g. H1299_LUNG in Campbell et al ) is NCIH1299_LUNG in our genotype set) we manually rename the screen dataset to match the genotype data.
Gene Identification
CancerGD provides links to multiple external sources that use a variety of different gene identifiers. Consequently for each gene in the database we store multiple identifiers (Entrez Gene ID, Ensembl Gene identifiers, HUGO Gene Names, Ensembl Protein IDs). We also store synonyms for each gene to facilitate easy gene look up (e.g. ERBB2 can be identified by searching for HER2). These synonyms are obtained from the HGNC resource (Gray et al., 2015) .
Drug Target Annotations
Drug-gene relationships are obtained from the Drug-Gene Interaction Database (DGIdb), which integrates drug-gene relationships from multiple sources (Wagner et al., 2016) . Only inhibitor relationships are retrieved, as we are interested in drugs that inhibit the products of specific genes, rather than drugs whose efficacy is associated with the mutation of specific genes. Results from DGIdb sourced from MyCancerGenome and MyCancerGenomeClinicalTrial are excluded for the same reason.
Functional Interactions
Functional interactions are obtained from STRING. We store all interactions that are medium confidence (STRING score > 0.4) or higher. Cut-offs to identify interactions as 'Medium', 'High' and 'Highest' confidence are those defined by STRING. For displaying the functional interactions between the dependencies associated with each driver gene we use the STRING API (Szklarczyk et al., 2015) .
Implementation
CancerGD is implemented in Python using the Django framework and follows a model/view/controller architecture. JQuery is used for Javascript processing in the browser interface. MySQL is used by default for data storage but SQLite can be used for development / testing purposes with minimal documented changes. The application is currently hosted on the PythonAnywhere system, a generic Python web services host, suggesting that the application is portable.
Formatting Screens for CancerGD
To enable easy inclusion of future screens in CancerGD we request that data be provided as a tab-delimited table with each row representing a particular cell line and each column representing reagents targeting a specific gene. Cell line names should preferably follow the Cancer Cell Line Encyclopaedia naming convention described above, but COSMIC IDs are also acceptable. Genes should preferably be identified using ENTREZ IDs but other unique IDs (ENSEMBL Gene IDs) are acceptable. Due to regular changing and updating, gene symbols alone should not be used as unique gene identifiers. We favour SYMBOL_ENTREZID (e.g KRAS_3846) for ease of use but this is not required. In cases where multiple distinct scores are provided for a specific gene, as happens with scores from the ATARIS algorithm, we request that they be identified using distinct suffixes (e.g. KRAS_3846_1, KRAS_3846_2).
Individual entries in the table should be quantitative scores indicating how sensitive a specific cell line is to perturbation of a particular gene. As different scoring procedures are used to quantify the results of screens using different experimental approaches
